Lv71
3688 积分 2022-01-17 加入
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
1小时前
求助中
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
5小时前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
5小时前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
1个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
1个月前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
3个月前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
3个月前
已完结
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
3个月前
已完结
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
5个月前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
5个月前
已完结
皖公网安备34019202002308
